Ambrx Shareholders Sue Over Proposed $2B J&J Deal
Two new suits filed in Delaware federal court allege Ambrx Biopharma Inc. and its top executives omitted important information about a $2 billion proposed Johnson & Johnson buyout in the deal's...To view the full article, register now.
Already a subscriber? Click here to view full article